2. Search Result
Search Result
Results for "

cytokine secretion

" in MedChemExpress (MCE) Product Catalog:

139

Inhibitors & Agonists

1

Screening Libraries

2

Biochemical Assay Reagents

12

Peptides

18

Inhibitory Antibodies

28

Natural
Products

9

Isotope-Labeled Compounds

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1081A
    Oxidopamine hydrobromide
    Maximum Cited Publications
    41 Publications Verification

    6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide

    		 Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase Neurological Disease Cancer
    Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .
    Oxidopamine hydrobromide
  • HY-B1081
    Oxidopamine hydrochloride
    Maximum Cited Publications
    41 Publications Verification

    6-Hydroxydopamine Hydrochloride

    		 Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase Neurological Disease Cancer
    Oxidopamine (6-OHDA) hydrochloride is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrochloride is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrochloride promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrochloride can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .
    Oxidopamine hydrochloride
  • HY-P9997
    Rosnilimab

    ANB030

    		 PD-1/PD-L1 Inflammation/Immunology
    Rosnilimab (ANB030) is a PD-1 agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high PD-1 expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .
    Rosnilimab
  • HY-N6796
    Manumycin A
    2 Publications Verification

    		 Antibiotic Exosomes Farnesyl Transferase Ras Apoptosis Phospholipase TNF Receptor Atg8/LC3 Infection Inflammation/Immunology Cancer
    Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion .
    Manumycin A
  • HY-172162
    LC-04-045

    		Molecular Glues NEKs Interleukin Related Inflammation/Immunology Cancer
    LC-04-045 is a selective NIMA-related kinase 7 (NEK7) molecular glue degrader. LC-04-045 induces NEK7 degradation via the CRBN-based ubiquitin-proteasome system, dependent on the glycine 57-containing degron motif. LC-04-045 inhibits secretion of downstream cytokines IL-1β and IL-18. LC-04-045 can be used for the research of lymphoblastic leukemia .
    LC-04-045
  • HY-136339
    Cbl-b-IN-1
    1 Publications Verification

    		 E1/E2/E3 Enzyme Interleukin Related Inflammation/Immunology Cancer
    Cbl-b-IN-1 (Example 519) is an inhibitor of Cbl-b, with an IC50 of less than 100 nM. Cbl-b-IN-1 can promote the secretion of cytokines such as IL-2, IFN-γ, and TNF-α, facilitate T cell activation, and enhance the TCR signaling pathway. Cbl-b-IN-1 can be used in research on immunomodulation .
    Cbl-b-IN-1
  • HY-30216A
    Leucic acid

    α-Hydroxyisocaproic acid

    		 Drug Metabolite Hydroxycarboxylic Acid Receptor (HCAR) AMPK ERK Metabolic Disease Inflammation/Immunology
    Leucic acid (α-Hydroxyisocaproic acid) is an orally active end-product of the microbial metabolism of leucine. Leucic acid can bind to HCAR2, alters AMPK and ERK1/2 phosphorylation status, suppresses lipid synthesis, promotes catabolism, reduces adiposity, enhances lean mass and exercise capacity. Leucic acid suppresses pro-inflammatory cytokine secretion, inflammation-related gene mRNA expression. Leucic acid decreases basal protein synthesis, attenuates myotube atrophy. Leucic acid can be used for the research of obesity .
    Leucic acid
  • HY-W013579
    (S)-(+)-Carvone

    D-​Carvone

    		 Environmental Pollutants Apoptosis Caspase Interleukin Related Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) SOD Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    (S)-(+)-Carvone is an orally active natural product. (S)-(+)-Carvone increases the activity of antioxidant enzymes (SOD, CAT) and ROS, reduces the levels of oxidative stress markers (MDA, AChE), reduces the secretion of proinflammatory cytokines (IL-1β, IL-4, IL-6, IL-10), and downregulates NLRP3. (S)-(+)-Carvone increases the activities of caspase-8, -9 and -3. (S)-(+)-Carvone induces apoptotic death. (S)-(+)-Carvone has antimanic-like effect, liver protection and anticancer activity against skin cancer. (S)-(+)-Carvone improves memory and arthritis .
    (S)-(+)-Carvone
  • HY-P1745
    InsB (9-23)

    Insulin B chain (9-23)

    		 MHC Insulin Receptor IFNAR Inflammation/Immunology
    InsB (9-23) (Insulin B chain (9-23)) is an HLA-DQ8-restricted insulin B-chain peptide composed of amino acid residues 9-23. InsB (9-23) serves as a major MHC II class-restricted antigen. InsB (9-23) supports the recognition and activation of T cells, stimulates the secretion of IFN-γ and cytokines, and induces cross-reactive immune responses. InsB (9-23)-specific CD4 T cells can initiate diabetes . InsB (9-23) can be used in research related to type 1 diabetes and autoimmune diabetes .
    InsB (9-23)
  • HY-107635
    TMN355
    1 Publications Verification

    		 Cyclophilin Cardiovascular Disease
    TMN355 is a potent chemical cyclophilin A inhibitor and reduces foam cell formation and cytokine secretion. TMN355 is used for atherosclerosis .
    TMN355
  • HY-P10439
    CVRARTR

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    CVRARTR is a programmed cell death ligand-1 (PD-L1) antagonist with a KD of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model. CVRARTR can be used in melanoma research .
    CVRARTR
  • HY-N7102
    Ceftiofur
    4 Publications Verification

    		 Antibiotic Bacterial NF-κB p38 MAPK TNF Receptor Interleukin Related Infection
    Ceftiofur is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 .
    Ceftiofur
  • HY-B0898
    Ceftiofur sodium
    4 Publications Verification

    sodium ceftiofur

    		 Antibiotic Bacterial NF-κB p38 MAPK TNF Receptor Interleukin Related Infection
    Ceftiofur sodium is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur sodium exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur sodium also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 .
    Ceftiofur sodium
  • HY-P99236
    Bexmarilimab
    1 Publications Verification

    FP-1305

    		 Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4 antibody with an IC50 value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can promote antigen presentation and pro-inflammatory cytokine secretion. Bexmarilimab can induce B-cell and T-cell activation. Bexmarilimab can be used in researches of immunology and cancer, such as colorectal carcinoma .
    Bexmarilimab
  • HY-W015892
    γ-Hexalactone

    γ-Caprolactone

    		 Interleukin Related TNF Receptor Insecticide Infection
    γ-Hexalactone (γ-Caprolactone) is a gamma-lactone found in ripe fruits. γ-Hexalactone induces DNA damage in human lymphocytes and HepG2 cells, modulates cytokine secretion in human lymphocytes, and reduces recombinant PON1 activity. γ-Hexalactone serves as a dose-dependent oviposition inhibitor against Bactrocera oleae. γ-Hexalactone can be used for the research of Bactrocera oleae pest management .
    γ-Hexalactone
  • HY-P99159
    Ivuxolimab

    		Interleukin Related Cancer
    Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4 + and CD8 + T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc .
    Ivuxolimab
  • HY-136065
    bpV(phen)
    3 Publications Verification

    		 PTEN Phosphatase Parasite Apoptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    bpV(phen), a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC50s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. bpV(phen) inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity .
    bpV(phen)
  • HY-N0600
    Ginsenoside F3

    		Interleukin Related IFNAR NF-κB Inflammation/Immunology
    Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a Kd value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer .
    Ginsenoside F3
  • HY-18325
    AN-3485
    1 Publications Verification

    		 Toll-like Receptor (TLR) NF-κB Interleukin Related Inflammation/Immunology Cancer
    AN-3485 is a benzoxaborole analogue and an orally active antagonist of the Toll-like pathway. AN-3485 can inhibit TLR-mediated inflammatory cytokine secretion and has significant anti-inflammatory activity. In addition, AN-3485 also has certain anti-tumor activity .
    AN-3485
  • HY-19553
    LP99

    		Epigenetic Reader Domain Inflammation/Immunology
    LP99, an epigenetic probe, is a potent and selective inhibitor of the BRD7 and BRD9 bromodomains with a Kd of 99 nM against BRD9. LP99 disrupts the binding of BRD7 and BRD9 to chromatin in cells .
    LP99
  • HY-P991257
    MK-1966
    1 Publications Verification

    		 Interleukin Related CXCR MHC Cancer
    MK-1966 is an anti-IL-10 antibody. MK-1966 inhibits secretion of cytokines from activated macrophages, production of CC and CXC chemokines, and a TH1 response, down-regulates MHC and costimulatory molecules on dendritic cells (DCs), and induces regulatory T cells. MK-1966 can be used for the research of cancer , such as gastric cancer .
    MK-1966
  • HY-150217A
    CpG ODN 10101 sodium
    2 Publications Verification

    ODN 10101 sodium

    		 Toll-like Receptor (TLR) Infection
    CpG ODN 10101 sodium, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist. CpG ODN 10101 sodium is a potent inducer of cytokine/chemokine expression ex vivo when used in combination with HH2(VQLRIRVAVIRA-NH2). CpG ODN 10101 sodium induces IFN- secretion from dendritic cells (DCs) and stimulates B-cells.CpG ODN 10101 sodium has antiviral and immunomodulatory properties that can influence chronic infection with HCV .
    CpG ODN 10101 sodium
  • HY-P11077
    LR-17

    TLT-1 (94-110)

    		 TREM receptor Inflammation/Immunology
    LR-17 (TLT-1 (94-110)), a 17-aa peptide, is a TREM-1 inhibitor. LR-17 shows anti-inflammatory effects that can reduce the secretion of pro-inflammatory cytokines induced by Lipopolysaccharides (HY-D1056) (LPS). LR-17 can be used for the study of sepsis .
    LR-17
  • HY-N8593
    Undecane

    		Environmental Pollutants p38 MAPK TNF Receptor NF-κB Interleukin Related Histamine Receptor PKA Inflammation/Immunology Endocrinology
    Undecane is a potent cAMP agonist with anti-allergic and anti-inflammatory activities. Undecane inhibits degranulation and the secretion of histamine and TNF-α. Undecane reverses the increased levels of p38 phosphorylation, NF-κB transcriptional activity and target cytokine/chemokine genes, including thymus and activation-regulated chemokine (TARC), macrophage-derived chemokine (MDC) and interleukin-8 (IL-8). Undecane can be used for the study of skin inflammatory disorders, such as atopic dermatitis .
    Undecane
  • HY-122818
    BpV(phen) trihydrate
    3 Publications Verification

    Bisperoxovanadium(phen) trihydrate

    		 PTEN Phosphatase Parasite Apoptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    BpV(phen) trihydrate, a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC50s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. BpV(phen) trihydrate inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) trihydrate strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). BpV(phen) trihydrate can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity .
    BpV(phen) trihydrate
  • HY-P10939A
    Ac-DMLD-CMK TFA

    		Caspase Pyroptosis Inflammation/Immunology Cancer
    Ac-DMLD-CMK TFA is a caspase 3 inhibitor and a GSDME inhibitor. Ac-DMLD-CMK TFA binds directly to the catalytic domain of caspase-3, blocks caspase-3-mediated cleavage of GSDME, inhibits the activation of caspase 3 and Gsdme in the caspase 3-Gsdme signaling pathway, and reduces the levels of pyroptosis and apoptosis as well as the expression of LDH, IL-6, IL-1β and IL-18. Ac-DMLD-CMK TFA alleviates renal function deterioration, renal tubular epithelial cell injury, inflammatory cytokine secretion, pulmonary structural damage, and chemotherapy-induced nephrotoxicity .
    Ac-DMLD-CMK TFA
  • HY-13743
    Roquinimex

    Linomide; FCF89; ABR212616

    		 TNF Receptor Interleukin Related IFNAR Neurological Disease Inflammation/Immunology Cancer
    Roquinimex (Linomide) is an orally active immunomodulator with antineoplastic, anti-inflammatory, and antiangiogenic activity. Roquinimex suppresses TH1 lymphocyte cytokines (IL-2, IFN-γ), promotes TH2 lymphocyte cytokines (IL-4, IL-10), increases NK cell, activated monocyte, and T cell activity. Roquinimex blocks macrophage TNF-α production and suppresses IL-1/IL-6 secretion. Roquinimex exhibits in vivo antitumour activity, suppresses rodent autoimmune disease signs, and ameliorates murine colitis and psoriasis. Roquinimex can be used for the research of leukemia, inflammatory bowel disease, multiple sclerosis, and psoriasis .
    Roquinimex
  • HY-P990781
    Suciraslimab

    SM03

    		 CD22 NOD-like Receptor (NLR) Interleukin Related Integrin Neurological Disease Inflammation/Immunology
    Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation . Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).
    Suciraslimab
  • HY-P991517
    BI-836858

    		Transmembrane Glycoprotein Reactive Oxygen Species (ROS) Cardiovascular Disease Cancer
    BI-836858 is a fully human anti-CD33 monoclonal antibody. BI-836858 reduces CD33+ cells via antibody-dependent cellular cytotoxicity (ADCC), blocks downstream signaling of S100A9/CD33, decreases the secretion of immunosuppressive cytokines and reactive oxygen species-induced genomic instability, and restores bone marrow hematopoietic function. BI-836858 is applicable to the research of myelodysplastic syndrome (MDS) and AML .
    BI-836858
  • HY-116227
    (2S,3R)-LP99

    		Epigenetic Reader Domain Inflammation/Immunology
    (2S,3R)-LP99 is a potent and selective BRD7 and BRD9 inhibitor with an KD of 99 nM for BRD9. (2S,3R)-LP99 inhibits the association of BRD7 and BRD9 to acetylated histones in vitro and in cells. (2S,3R)-LP99 demonstrates that BRD7/9 plays a role in regulating pro-inflammatory cytokine secretion .
    (2S,3R)-LP99
  • HY-P10939
    Ac-DMLD-CMK

    		Caspase Pyroptosis Inflammation/Immunology Cancer
    Ac-DmLD-CMK is a caspase 3 inhibitor and a GSDME inhibitor. Ac-DmLD-CMK binds directly to the catalytic domain of caspase-3, blocks caspase-3-mediated cleavage of GSDME, inhibits the activation of caspase 3 and Gsdme in the caspase 3-Gsdme signaling pathway, and reduces the levels of pyroptosis and apoptosis as well as the expression of LDH, IL-6, IL-1β and IL-18. Ac-DmLD-CMK alleviates renal function deterioration, renal tubular epithelial cell injury, inflammatory cytokine secretion, pulmonary structural damage, and chemotherapy-induced nephrotoxicity .
    Ac-DMLD-CMK
  • HY-N6927
    Isoforskolin

    Coleonol B

    		 TNF Receptor Interleukin Related Inflammation/Immunology
    Isoforskolin is the principle active component of C. forskohlii native to China. Isoforskolin reduces the secretion of lipopolysaccharide (LPS)-induced cytokines, namely TNF-α, IL-1β, IL-6 and IL-8, in human mononuclear leukocytes. Isoforskolin acts as an anti-inflammatory agent for the treatment of Lyme arthritis .
    Isoforskolin
  • HY-169853
    M351-0056

    		VISTA Inflammation/Immunology
    M351-0056 is the agonist for the immune checkpoint protein VISTA, that reduces the secretion of VISTA-induced cytokines, promotes the T-cell proliferation induced by VISTA, and exhibits immunomodulatory activity. M351-0056 ameliorates Imiquimod (HY-B0180)-induced psoriatic dermatitis in mouse models .
    M351-0056
  • HY-134000
    Emodic acid

    NSC624610

    		 p38 MAPK NF-κB ERK JNK VEGFR MMP Cancer
    Emodic acid (NSC624610) is an anthraquinone compound isolated from A. microcarpus, which can inhibit the proliferation of cancer cells by inhibiting the activity of NF-κB. Emodic acid can also inhibit the phosphorylation of p38, ERK and JNK, the secretion of tumor-promoting cytokines IL-1β and IL-6, and the expression of VEGF and MMP, thereby inhibiting the invasion and migration potential of cancer cells .
    Emodic acid
  • HY-B0026
    Ceftiofur hydrochloride
    4 Publications Verification

    		 Antibiotic Bacterial NF-κB p38 MAPK TNF Receptor Interleukin Related Infection
    Ceftiofur hydrochloride is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur hydrochloride exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur hydrochloride also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 .
    Ceftiofur hydrochloride
  • HY-N14780
    Pochonin D

    (+)-Pochonin D

    		 HSP Interleukin Related Enterovirus Infection Inflammation/Immunology Cancer
    Pochonin D ((+)-Pochonin D) is an inhibitor of heat shock protein 90 (Hsp90) with antiviral and anti-inflammatory activities. Pochonin D inhibits Hsp90, affects the homeostasis, folding and assembly processes of viral proteins, and reduces the replication capacity of viruses. Pochonin D reduces the infiltration of inflammatory cells, decreases the secretion of inflammatory cytokines such as TNF-α and IL-1β, and alleviates inflammatory responses. Pochonin D is a promising candidate for research on human rhinovirus (HRV) infection and cancer .
    Pochonin D
  • HY-B0898R
    Ceftiofur sodium (Standard)

    sodium ceftiofur (Standard)

    		 Reference Standards Antibiotic Bacterial NF-κB p38 MAPK TNF Receptor Interleukin Related Infection
    Ceftiofur sodium (Standard) is the analytical standard of Ceftiofur sodium (HY-B0898). This product is intended for research and analytical applications. Ceftiofur sodium is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur sodium exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur sodium also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 .
    Ceftiofur sodium (Standard)
  • HY-P5641
    Pleurocidin
    1 Publications Verification

    		 Bacterial p38 MAPK NF-κB NADH Dehydrogenase Antibiotic Infection Inflammation/Immunology
    Pleurocidin is an Antimicrobial peptide. Pleurocidin is derived from the skin mucosa or intestinal secretions of Pseudopleuronectes americanus. Pleurocidin inhibits the expression of key proteins in the MAPK and NF-κB inflammatory signaling pathways. Pleurocidin alters serum inflammatory and immune cytokine levels, regulates the down-regulation of tight junction proteins, and modulates the intestinal flora. Pleurocidin exerts antibacterial activity by inducing bacterial membrane damage, hydroxyl radical formation, and NADH depletion, and also produces a synergistic effect with Antibiotics. Pleurocidin alleviates DSS-induced ulcerative colitis. Pleurocidin can be used for research on ulcerative colitis, bacterial infections, and bacterial biofilm-related infections .
    Pleurocidin
  • HY-175876
    ADAM17-IN-1

    		MMP Interleukin Related Inflammation/Immunology
    ADAM17-IN-1 is a selective inhibitor of ADAM17. ADAM17-IN-1 inhibits ADAM17 activity to reduce metabolic activity of dendritic cells (DCs), impair DC antigen-presenting function, suppress allergen-specific Th2 cell polarization, and reduce Th2 cytokine (IL-4, IL-5, IL-13) secretion. ADAM17-IN-1 demonstrates protective efficacy against house dust mite (HDM)-induced type 2/eosinophilic airway inflammation in mice. ADAM17-IN-1 can be used for the study of type 2-high allergic asthma .
    ADAM17-IN-1
  • HY-164386
    Defoslimod

    OM 174

    		 Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    Defoslimod (OM 174) is an agonist for TLR4 receptor and acts as an immunomodulator. Defoslimod activates macrophages and dendritic cells, induces cytokines secretion, and exhibits antitumor efficacy in rats .
    Defoslimod
  • HY-179336
    TLR7/8 agonist 14

    		Toll-like Receptor (TLR) Interleukin Related IFNAR TNF Receptor Cancer
    TLR7/8 agonist 14 is a TLR7 and TLR8 agonist with EC50 values of 0.53 μM and 4.3 μM, respectively. TLR7/8 agonist 14 increases the secretion of the proinflammatory cytokines TNF-α, IL-1β, IL-8 and IFN-γ. TLR7/8 agonist 14 increases cytokine secretion and expression of CD86. LR7/8 agonist 14 can be used for research colorectal carcinoma .
    TLR7/8 agonist 14
  • HY-134375
    cAIMP

    Cyclic Adenosine-Inosine Monophosphate

    		 NF-κB IFNAR Inflammation/Immunology
    cAIMP (Cyclic Adenosine-Inosine Monophosphate) is an effective synthetic cyclic dinucleotide. cAIMP activates IRF and NF-κB in the THP1 human monocyte reporter cell line (THP1-Dual). cAIMP induces the secretion of IFNs and pro-inflammatory cytokines in vitro in human blood, with an EC50 of 6.4 μmol/L .
    cAIMP
  • HY-174142
    IHMT-15130

    		BMX Kinase Cardiovascular Disease Inflammation/Immunology
    IHMT-15130 is a highly potent irreversible BMX kinase inhibitor (IC50=1.47 nM). IHMT-15130 inhibits the secretion of inflammatory cytokines, blocks inflammatory signaling pathways, and alleviates Angiotensin II-induced myocardial hypertrophy in mice. IHMT-15130 is promising for research of myocardial hypertrophy .
    IHMT-15130
  • HY-178012
    GLPG4471

    		IRAK TNF Receptor Inflammation/Immunology
    GLPG4471 is a selective and orally active IRAK4 inhibitor with an IC50 of 1.7 nM. GLPG4471 exhibits potent inhibition of cytokine (TNFα and IFNα) secretion in cellular and whole blood phenotypic assays. GLPG4471 displays significant activity in a mouse model of collagen-induced arthritis. GLPG4471 can be used for the study of arthritis .
    GLPG4471
  • HY-177130S
    Socrodeucitinib

    		JAK Inflammation/Immunology
    Socrodeucitinib (Compound Example 58) is an orally active and selective tyrosine kinase 2 (TYK2) inhibitor with an IC50 value of 1.41 nM. Socrodeucitinib exerts anti-inflammatory activity by inhibiting TYK2-mediated cytokine signaling pathways and reducing the secretion of inflammatory factors. Socrodeucitinib is promising for research of autoimmune diseases such as psoriasis and inflammatory diseases .
    Socrodeucitinib
  • HY-Q40876
    BBT

    		Calcium Channel Metabolic Disease
    BBT is an enhancer of impaired glucose-stimulated insulin secretion (GSIS). BBT exhibits anti-hyperglycemia activity, and protects β-cells from cytokine- or streptozotocin (STZ (HY-13753))-induced cell death in type 2 diabetes models. BBT acts function via cAMP/PKA and long-lasting (L-type) voltage-dependent Ca2+ channel/CaMK2 pathway .
    BBT
  • HY-P991610
    S-095029

    Sym025

    		 C-type Lectin-like Receptors (CTLRs) Cancer
    S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
    S-095029
  • HY-P990031
    Dargistotug

    M-6223

    		 Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
    Dargistotug
  • HY-N17239
    Oleracone

    		TNF Receptor Interleukin Related NO Synthase Inflammation/Immunology
    Oleracone is a type of alkaloid that can be found in Portulaca oleracea L.. Oleracone exhibits a significant anti-inflammatory effect in the RAW 264.7 macrophage model induced by LPS (HY-D1056), capable of inhibiting NO production and significantly suppressing the secretion of pro-inflammatory cytokines TNF-α, IL-6, and prostaglandin E₂ (PGE₂). Oleracone can be used for the study of inflammatory diseases .
    Oleracone
  • HY-161630
    TLR8 agonist 8

    		Toll-like Receptor (TLR) Cancer
    TLR8 agonist 8 (Compound II-72) is an agonist for Toll-like receptor 8 (TLR8) with EC50 of 0.25-1 μM. TLR8 agonist 8 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC50 <1 μM. TLR8 agonist 8 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 89% .
    TLR8 agonist 8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: